Vyloy

1st-line treatment in combination w/ fluoropyrimidine- & platinum-containing chemotherapy in patients w/ locally advanced unresectable or metastatic human epidermal growth factor receptor 2 -ve gastric or gastroesophageal junction adenocarcinoma whose tumors are Claudin 18.2 +ve.

IV Infuse over a min of 2 hr. Administer in combination w/ fluoropyrimidine- & platinum-containing chemotherapy. Pretreatment: Premedicate w/ antiemetics prior to each infusion. Consider systemic corticosteroids particularly before 1st infusion of zolbetuximab. Single loading dose 800 mg/m² (cycle 1, day 1). Infusion rate: 100 mg/m²/hr for the 1st 30-60 min & 200-400 mg/m²/hr for the remaining infusion time. Maintenance dose 600 mg/m² every 3 wk (infusion rate: 75 mg/m²/hr for the 1st 30-60 min & 150-300 mg/m²/hr for the remaining infusion time) or 400 mg/m² every 2 wk (infusion rate: 50 mg/m²/hr for the 1st 30-60 min & 100-200 mg/m²/hr for the remaining infusion time).

Hypersensitivity.

Targeted Cancer Therapy

L01FX31 - zolbetuximab ; Belongs to the class of other monoclonal antibodies and antibody drug conjugates. Used in the treatment of cancer.

POM